February 2025 in “International Journal of Morphology” Vitamin E can reduce the negative effects of valproic acid on hair and skin development.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
Sodium valproate improved epilepsy control in most children but often caused weight gain and other mild side effects.
January 2017 in “SHILAP Revista de lepidopterología” Agomelatine might help reduce hair loss caused by valproate.
1 citations
,
January 2024 in “Skin research and technology” Deoxycholic acid is FDA-approved for reducing submental fat, but its mechanisms are not fully understood.
69 citations
,
December 2005 in “Nature Clinical Practice Endocrinology & Metabolism” Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.
December 2006 in “The Brown University Psychopharmacology Update” Second-generation antipsychotics offer no significant benefit over first-generation ones for schizophrenia.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
5 citations
,
July 2024 in “Archives of Dermatological Research” 1 citations
,
May 1992 in “Pharmacological Research”
1 citations
,
December 2022 in “Journal of cosmetic dermatology” The combination of vitamin D analogues with potent steroids is a favorable treatment for alopecia areata with fewer side effects.
2 citations
,
May 2021 in “Clinical Pharmacology in Drug Development” Clascoterone is safe for the heart, even at high doses.
January 2024 in “Acta dermato-venereologica”
25 citations
,
December 1974 in “Clinical Pharmacology & Therapeutics” Propranolol affects heart rate and renin levels in minoxidil-treated patients.
33 citations
,
May 1991 in “British Journal of Pharmacology” Cromakalim relaxes various blood vessels, while minoxidil sulphate is more selective; they likely act on different potassium channels.
46 citations
,
September 2011 in “Journal of Endocrinology” Natural 5α-reduced glucocorticoids might be anti-inflammatory with fewer side effects than current options.
1 citations
,
February 2025 in “Toxicology in Vitro” Diphlorethohydroxycarmalol may help treat hair loss better than current medications.
November 2024 in “Journal of Cosmetic Dermatology” Valproic acid microemulsions improve skin delivery compared to regular solutions.
4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
May 2024 in “International journal of medicine and psychology.” Ibuprofen is more effective than acetaminophen for reducing pain and inflammation after wisdom tooth removal.
August 1994 in “Drugs & Therapy Perspectives” The document concludes that H2-antagonists and proton pump inhibitors are highly effective for ulcers, eradicating Helicobacter pylori is important to prevent recurrence, and misoprostol helps with NSAID-related ulcers.
September 2025 in “Arthritis Research & Therapy” BMS-470539 reduces skin fibrosis and inflammation.
December 2025 in “Cosmoderma” Systemic corticosteroids help manage vitiligo by slowing progression and aiding repigmentation.
June 2020 in “Annals of the Rheumatic Diseases” Patients need better information about the risks of long-term steroid use.
201 citations
,
May 2001 in “Proceedings of the National Academy of Sciences” Overexpression of COX-2 in mice skin causes abnormal skin and hair development.
January 2025 in “Recent Patents on Anti-Cancer Drug Discovery” The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
2-Hydroxy-1,4-naphthoquinone is a strong 5α-reductase inhibitor.
2 citations
,
January 2012 in “Journal of Clinical & Experimental Dermatology Research” Fexofenadine reduces discomfort but doesn't significantly improve hair regrowth in Alopecia Areata treatment.
31 citations
,
April 2016 in “Journal of the American Academy of Dermatology” This study evaluated the efficacy and safety of pulse corticosteroid therapy with oral dexamethasone (PCT-OD) for treating adult alopecia totalis (AT) and universalis (AU). Involving 31 patients, the study found an 80.6% therapeutic response rate, with 71% achieving complete regrowth. All patients with AT had a complete response, and adverse effects were observed in 32% of participants, including weight gain and Cushing syndrome. The study concluded that PCT-OD at 0.1 mg/kg/day biweekly was a potential therapeutic option for AT/AU, although the absence of a control group was a limitation.